Selected research
Industry Research
Nateglinide Industry Research Report 2026
Market perspective
The global Nateglinide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nateglinide market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nateglinide market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nateglinide market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nateglinide include Qilu Pharmaceutical Co., Ltd, Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant, Jiangsu Deyuan Pharmaceutical Co. Ltd, Beijing Novartis Pharmaceutical Co. Ltd, Nivagen Pharmaceuticals, Inc., NIKSAN PHARMACEUTICAL, Caremark L.L.C. and AvKARE, Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nateglinide market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nateglinide.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nateglinide Market by Company
Qilu Pharmaceutical Co., Ltd
Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant
Jiangsu Deyuan Pharmaceutical Co. Ltd
Beijing Novartis Pharmaceutical Co. Ltd
Nivagen Pharmaceuticals, Inc.
NIKSAN PHARMACEUTICAL
Caremark L.L.C.
AvKARE, Inc.
Nateglinide Segment by Type
Tablet
Capsule
Nateglinide Segment by Application
Used In Combination With Metformin
Used Alone
Nateglinide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nateglinide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nateglinide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nateglinide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nateglinide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Capsule
Applications
- Used In Combination With Metformin
- Used Alone
Companies covered
- Qilu Pharmaceutical Co., Ltd
- Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant
- Jiangsu Deyuan Pharmaceutical Co. Ltd
- Beijing Novartis Pharmaceutical Co. Ltd
- Nivagen Pharmaceuticals, Inc.
- NIKSAN PHARMACEUTICAL
- Caremark L.L.C.
- AvKARE, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nateglinide by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tablet
- 2.2.3 Capsule
- 2.3 Nateglinide by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Used In Combination With Metformin
- 2.3.3 Used Alone
- 2.4 Assumptions and Limitations
3 Nateglinide Breakdown Data by Type
- 3.1 Global Nateglinide Historic Market Size by Type (2021-2026)
- 3.2 Global Nateglinide Forecasted Market Size by Type (2027-2032)
4 Nateglinide Breakdown Data by Application
- 4.1 Global Nateglinide Historic Market Size by Application (2021-2026)
- 4.2 Global Nateglinide Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nateglinide Market Perspective (2021-2032)
- 5.2 Global Nateglinide Growth Trends by Region
- 5.2.1 Global Nateglinide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nateglinide Historic Market Size by Region (2021-2026)
- 5.2.3 Nateglinide Forecasted Market Size by Region (2027-2032)
- 5.3 Nateglinide Market Dynamics
- 5.3.1 Nateglinide Industry Trends
- 5.3.2 Nateglinide Market Drivers
- 5.3.3 Nateglinide Market Challenges
- 5.3.4 Nateglinide Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nateglinide Players by Revenue
- 6.1.1 Global Top Nateglinide Players by Revenue (2021-2026)
- 6.1.2 Global Nateglinide Revenue Market Share by Players (2021-2026)
- 6.2 Global Nateglinide Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nateglinide Head Office and Area Served
- 6.4 Global Nateglinide Players, Product Type & Application
- 6.5 Global Nateglinide Manufacturers Established Date
- 6.6 Global Nateglinide Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nateglinide Market Size (2021-2032)
- 7.2 North America Nateglinide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nateglinide Market Size by Country (2021-2026)
- 7.4 North America Nateglinide Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nateglinide Market Size (2021-2032)
- 8.2 Europe Nateglinide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nateglinide Market Size by Country (2021-2026)
- 8.4 Europe Nateglinide Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nateglinide Market Size (2021-2032)
- 9.2 Asia-Pacific Nateglinide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nateglinide Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nateglinide Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nateglinide Market Size (2021-2032)
- 10.2 South America Nateglinide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nateglinide Market Size by Country (2021-2026)
- 10.4 South America Nateglinide Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nateglinide Market Size (2021-2032)
- 11.2 Middle East & Africa Nateglinide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nateglinide Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nateglinide Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Qilu Pharmaceutical Co., Ltd
- 12.1.1 Qilu Pharmaceutical Co., Ltd Company Information
- 12.1.2 Qilu Pharmaceutical Co., Ltd Business Overview
- 12.1.3 Qilu Pharmaceutical Co., Ltd Revenue in Nateglinide Business (2021-2026)
- 12.1.4 Qilu Pharmaceutical Co., Ltd Nateglinide Product Portfolio
- 12.1.5 Qilu Pharmaceutical Co., Ltd Recent Developments
- 12.2 Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant
- 12.2.1 Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant Company Information
- 12.2.2 Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant Business Overview
- 12.2.3 Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant Revenue in Nateglinide Business (2021-2026)
- 12.2.4 Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant Nateglinide Product Portfolio
- 12.2.5 Chen Ho Pharmaceutical Co.,Ltd.Sinying Plant Recent Developments
- 12.3 Jiangsu Deyuan Pharmaceutical Co. Ltd
- 12.3.1 Jiangsu Deyuan Pharmaceutical Co. Ltd Company Information
- 12.3.2 Jiangsu Deyuan Pharmaceutical Co. Ltd Business Overview
- 12.3.3 Jiangsu Deyuan Pharmaceutical Co. Ltd Revenue in Nateglinide Business (2021-2026)
- 12.3.4 Jiangsu Deyuan Pharmaceutical Co. Ltd Nateglinide Product Portfolio
- 12.3.5 Jiangsu Deyuan Pharmaceutical Co. Ltd Recent Developments
- 12.4 Beijing Novartis Pharmaceutical Co. Ltd
- 12.4.1 Beijing Novartis Pharmaceutical Co. Ltd Company Information
- 12.4.2 Beijing Novartis Pharmaceutical Co. Ltd Business Overview
- 12.4.3 Beijing Novartis Pharmaceutical Co. Ltd Revenue in Nateglinide Business (2021-2026)
- 12.4.4 Beijing Novartis Pharmaceutical Co. Ltd Nateglinide Product Portfolio
- 12.4.5 Beijing Novartis Pharmaceutical Co. Ltd Recent Developments
- 12.5 Nivagen Pharmaceuticals, Inc.
- 12.5.1 Nivagen Pharmaceuticals, Inc. Company Information
- 12.5.2 Nivagen Pharmaceuticals, Inc. Business Overview
- 12.5.3 Nivagen Pharmaceuticals, Inc. Revenue in Nateglinide Business (2021-2026)
- 12.5.4 Nivagen Pharmaceuticals, Inc. Nateglinide Product Portfolio
- 12.5.5 Nivagen Pharmaceuticals, Inc. Recent Developments
- 12.6 NIKSAN PHARMACEUTICAL
- 12.6.1 NIKSAN PHARMACEUTICAL Company Information
- 12.6.2 NIKSAN PHARMACEUTICAL Business Overview
- 12.6.3 NIKSAN PHARMACEUTICAL Revenue in Nateglinide Business (2021-2026)
- 12.6.4 NIKSAN PHARMACEUTICAL Nateglinide Product Portfolio
- 12.6.5 NIKSAN PHARMACEUTICAL Recent Developments
- 12.7 Caremark L.L.C.
- 12.7.1 Caremark L.L.C. Company Information
- 12.7.2 Caremark L.L.C. Business Overview
- 12.7.3 Caremark L.L.C. Revenue in Nateglinide Business (2021-2026)
- 12.7.4 Caremark L.L.C. Nateglinide Product Portfolio
- 12.7.5 Caremark L.L.C. Recent Developments
- 12.8 AvKARE, Inc.
- 12.8.1 AvKARE, Inc. Company Information
- 12.8.2 AvKARE, Inc. Business Overview
- 12.8.3 AvKARE, Inc. Revenue in Nateglinide Business (2021-2026)
- 12.8.4 AvKARE, Inc. Nateglinide Product Portfolio
- 12.8.5 AvKARE, Inc. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst